Combined therapies of bone disease with bisphosphonates

Current Pharmaceutical Design

Volumn 16, Issue 27, 2010, Pages 2988-2997

  Syddall, S P ^a   Ottewell, P D ^a   Holen, I ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Bone; Metastatic bone disease; Synergy; Zoledronic acid

Indexed keywords

4 [5 (4 CHLOROPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]BENZENESULFONAMIDE; ALENDRONIC ACID; ANASTROZOLE; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; DOXYCYCLINE; EPIRUBICIN; ETIDRONIC ACID; FLUOROURACIL; GEFITINIB; GOSERELIN; IBANDRONIC ACID; IMATINIB; METHOTREXATE; PACLITAXEL; PAMIDRONIC ACID; RISEDRONIC ACID; TAMOXIFEN; TILUDRONIC ACID; UFT; ZOLEDRONIC ACID;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE DISEASE; BONE METASTASIS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CELL GROWTH; CLINICAL STUDY; DISEASE FREE SURVIVAL; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; GROWTH INHIBITION; HUMAN; IC 50; IN VITRO STUDY; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; BONE RESORPTION; BREAST NEOPLASMS; DIPHOSPHONATES; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; NEOPLASMS; PROSTATIC NEOPLASMS;

EID: 78649834555     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210793563590     Document Type: Article

References (68)

1. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006; 12(20 Pt 2): 6243s-9.
2. Benford HL, McGowan NW, Helfrich MH, Nuttall ME, Rogers MJ. Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro. Bone 2001; 28(5): 465-73.
3. Rogers MJ, Gordon S, Benford HL, et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer 2000; 88(12 Suppl): 2961-78.
4. Stresing V, Daubine F, Benzaid I, Monkkonen H, Clezardin P. Bisphosphonates in cancer therapy. Cancer Lett 2007; 257(1): 16-35.
5. Senaratne SG, Pirianov G, Mansi JL, Arnett TR, Colston KW. Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer 2000; 82(8): 1459-68.
6. Fromigue O, Lagneaux L, Body JJ. Bisphosphonates induce breast cancer cell death in vitro. J Bone Miner Res 2000; 15(11): 2211-21.
7. Verdijk R, Franke HR, Wolbers F, Vermes I. Differential effects of bisphosphonates on breast cancer cell lines. Cancer Lett 2007; 246(1-2): 308-12.
8. Lee MV, Fong EM, Singer FR, Guenette RS. Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res 2001; 61(6): 2602-8.
9. Oades GM, Senaratne SG, Clarke IA, Kirby RS, Colston KW. Nitrogen containing bisphosphonates induce apoptosis and inhibit the mevalonate pathway, impairing Ras membrane localization in prostate cancer cells. J Urol 2003; 170(1): 246-52.
10. Sewing L, Steinberg F, Schmidt H, Goke R. The bisphosphonate zoledronic acid inhibits the growth of HCT-116 colon carcinoma cells and induces tumor cell apoptosis. Apoptosis 2008; 13(6): 782-9.
11. Tassone P, Tagliaferri P, Viscomi C, et al. Zoledronic acid induces antiproliferative and apoptotic effects in human pancreatic cancer cells in vitro. Br J Cancer 2003; 88(12): 1971-8.
12. Shipman CM, Rogers MJ, Apperley JF, Russell RG, Croucher PI. Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity. Br J Haematol 1997; 98(3): 665-72.
13. Li YY, Chang JW, Chou WC, et al. Zoledronic acid is unable to induce apoptosis, but slows tumor growth and prolongs survival for non-small-cell lung cancers. Lung Cancer 2008; 59(2): 180-91.
14. Winter MC, Holen I, Coleman RE. Exploring the anti-tumour activity of bisphosphonates in early breast cancer. Cancer Treat Rev 2008; 34(5): 453-75.
15. Saeki T, Sasaki Y, Itoh K, et al. Zoledronate (ZOL): phase I and pharmacokinetics (PK)/pharmacodynamics (PD) study in cancer patients. Bone 2000; 26(41S).
16. Jagdev SP, Coleman RE, Shipman CM, Rostami HA, Croucher PI. The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer 2001; 84(8): 1126-34.
17. Lin JH. Bisphosphonates: a review of their pharmacokinetic properties. Bone 1996; 18(2): 75-85.
18. Weiss HM, Pfaar U, Schweitzer A, Wiegand H, Skerjanec A, Schran H. Biodistribution and plasma protein binding of zoledronic acid. Drug Metab Dispos 2008; 36(10): 2043-9.
19. van der Pluijm G, Vloedgraven H, van Beek E, van der Wee-Pals L, Lowik C, Papapoulos S. Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J Clin Invest 1996; 98(3): 698-705.
20. Boissier S, Magnetto S, Frappart L, et al. Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res 1997; 57(18): 3890-4.
21. Boissier S, Ferreras M, Peyruchaud O, et al. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res 2000; 60(11): 2949-54.
22. Giraudo E, Inoue M, Hanahan D. An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Invest 2004; 114(5): 623-33.
23. Matsumoto S, Kimura S, Segawa H, et al. Efficacy of the thirdgeneration bisphosphonate, zoledronic acid alone and combined with anti-cancer agents against small cell lung cancer cell lines. Lung Cancer 2005; 47(1): 31-9.
24. Stathopoulos GT, Moschos C, Loutrari H, et al. Zoledronic acid is effective against experimental malignant pleural effusion. American. J Respir Crit Care Med 2008; 178(1): 50-9.
25. Yamagishi S-i, Abe R, Inagaki Y, et al. Minodronate, a newly developed nitrogen-containing bisphosphonate, suppresses melanoma growth and improves survival in nude mice by blocking vascular endothelial growth factor signaling. Am J Pathol 2004; 165(6): 1865-74.
26. Wada A, Fukui K, Sawai Y, et al. Pamidronate induced antiproliferative, apoptotic, and anti-migratory effects in hepatocellular carcinoma. J Hepatol 2006; 44(1): 142-50.
27. Li YY, Chang JW, Chou WC, et al. Zoledronic acid is unable to induce apoptosis, but slows tumor growth and prolongs survival for non-small-cell lung cancers. Lung Cancer 2008; 59(2): 180-91.
28. Coscia M, Quaglino E, Iezzi M, et al. Zoledronic acid repolarizes tumor-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway. J Cell Mol Med 2009; 10: 10.
29. Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Postlberger S, Menzel C, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009; 360(7): 679-91.
30. Sasaki A, Boyce BF, Story B, et al. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res 1995; 55(16): 3551-7.
31. Hiraga T, Williams PJ, Mundy GR, Yoneda T. The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases. Cancer Res 2001; 61(11): 4418-24.
32. Michigami T, Hiraga T, Williams PJ, et al. The effect of the bisphosphonate ibandronate on breast cancer metastasis to visceral organs. Breast Cancer Res Treat 2002; 75(3): 249-58.
33. Hiraga T, Williams PJ, Ueda A, Tamura D, Yoneda T. Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model. Clin Cancer Res 2004; 10(13): 4559-67.
34. Ory B, Heymann MF, Kamijo A, Gouin F, Heymann D, Redini F. Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma-bearing mice. Cancer 2005; 104(11): 2522-9.
35. Daubine F, Le Gall C, Gasser J, Green J, Clezardin P. Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis. J Natl Cancer Inst 2007; 99(4): 322-30.
36. Santini D, Vincenzi B, Galluzzo S, et al. Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients. Clin Cancer Res 2007; 13(15 Pt 1): 4482-6.
37. Corey E, Brown LG, Quinn JE, et al. Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer. Clin Cancer Res 2003; 9(1): 295-306.
38. Croucher PI, De Hendrik R, Perry MJ, et al. Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival. J Bone Miner Res 2003; 18(3): 482-92.
39. Gao L, Deng H, Zhao H, et al. HTLV-1 Tax transgenic mice develop spontaneous osteolytic bone metastases prevented by osteoclast inhibition. Blood 2005, 106(13): 4294-302.
40. Roelofs AJ, Coxon FP, Ebetino FHet al. Fluorescent risedronate analogs reveal bisphosphonate uptake by bone marrow monocytes and localization around osteocytes in vivo. J Bone Miner Res 2009; 12: 12.
41. Guise TA, Mohammad KS, Clines G, et al. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin Cancer Res 2006; 12(20 Pt 2): 6213s-6.
42. Neville-Webbe HL, Evans CA, Coleman RE, Holen I. Mechanisms of the synergistic interaction between the bisphosphonate zoledronic acid and the chemotherapy agent paclitaxel in breast cancer cells in vitro. Tumour Biol 2006; 27(2): 92-103.
43. Witters LM, Crispino J, Fraterrigo T, Green J, Lipton A. Effect of the combination of docetaxel, zoledronic acid, and a COX-2 inhibitor on the growth of human breast cancer cell lines. Am J Clin Oncol 2003; 26(4): S92-7.
44. Ullen A, Lennartsson L, Harmenberg U, et al. Additive/synergistic antitumoral effects on prostate cancer cells in vitro following treatment with a combination of docetaxel and zoledronic acid. Acta Oncol 2005; 44(6): 644-50.
45. Morgan C, Lewis PD, Jones RM, Bertelli G, Thomas GA, Leonard RC. The in vitro anti-tumour activity of zoledronic acid and docetaxel at clinically achievable concentrations in prostate cancer. Acta Oncol 2007; 46(5): 669-77.
46. Fabbri F, Brigliadori G, Carloni S, et al. Zoledronic acid increases docetaxel cytotoxicity through pMEK and Mcl-1 inhibition in a hormone-sensitive prostate carcinoma cell line. J Transl Med 2008; 6(43): 43.
47. Neville-Webbe HL, Rostami-Hodjegan A, Evans CA, Coleman RE, Holen I. Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells. Int J Cancer 2005; 113(3): 364-71.
48. Clyburn RD, Reid P, Evans CA, Lefley DV, Holen I. Increased anti-tumour effects of doxorubicin and zoledronic acid in prostate cancer cells in vitro: supporting the benefits of combination therapy. Cancer Chemother Pharmacol 2010; 65(5): 969-78.
49. Woodward JK, Neville-Webbe HL, Coleman RE, Holen I. Combined effects of zoledronic acid and doxorubicin on breast cancer cell invasion in vitro. Anticancer Drugs 2005; 16(8): 845-54.
50. Magnetto S, Boissier S, Delmas PD, Clezardin P. Additive antitumor activities of taxoids in combination with the bisphosphonate ibandronate against invasion and adhesion of human breast carcinoma cells to bone. Int J Cancer 1999; 83(2): 263-9.
51. Vogt U, Bielawski KP, Bosse U, Schlotter CM. Breast tumour growth inhibition in vitro through the combination of cyclophosphamide/ metotrexate/5-fluorouracil, epirubicin/cyclophosphamide, epirubicin/paclitaxel, and epirubicin/docetaxel with the bisphosphonates ibandronate and zoledronic acid. Oncol Rep 2004; 12(5): 1109-14.
52. Santini D, Caraglia M, Vincenzi B et al. Mechanisms of disease: Preclinical reports of antineoplastic synergistic action of bisphosphonates. Nat Clin Pract Oncol 2006; 3(6): 325-38.
53. Hiraga T, Ueda A, Tamura D, et al. Effects of oral UFT combined with or without zoledronic acid on bone metastasis in the 4T1/luc mouse breast cancer. Int J Cancer 2003; 106(6): 973-9.
54. Duivenvoorden WC, Vukmirovic-Popovic S, Kalina M, Seidlitz E, Singh G. Effect of zoledronic acid on the doxycycline-induced decrease in tumour burden in a bone metastasis model of human breast cancer. Br J Cancer 2007; 96(10): 1526-31.
55. van Beek ER, Lowik CW, van Wijngaarden J, Ebetino FH, Papapoulos SE. Synergistic effect of bisphosphonate and docetaxel on the growth of bone metastasis in an animal model of established metastatic bone disease. Breast Cancer Res Treat 2009; 118(2): 307-13.
56. Ottewell PD, Deux B, Monkkonen H, et al. Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo. Clin Cancer Res 2008; 14(14): 4658-66.
57. Ottewell PD, Monkkonen H, Jones M, Lefley DV, Coleman RE, Holen I. Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer. J Natl Cancer Inst 2008; 100(16): 1167-78.
58. Ottewell PD, Lefley DV, Cross SS, Evans CA, Coleman RE, Holen I. Sustained inhibition of tumor growth and prolonged survival following sequential administration of doxorubicin and zoledronic acid in a breast cancer model. Int J Cancer 2010; 126(2): 522-32.
59. Ottewell PD, Woodward JK, Lefley DV, Evans CA, Coleman RE, Holen I. Anticancer mechanisms of doxorubicin and zoledronic acid in breast cancer tumor growth in bone. Mol Cancer Ther 2009; 8(10): 2821-32.
60. Brubaker KD, Brown LG, Vessella RL, Corey E. Administration of zoledronic acid enhances the effects of docetaxel on growth of prostate cancer in the bone environment. BMC Cancer 2006; 6(15): 15.
61. Kim SJ, Uehara H, Yazici S, et al. Modulation of bone microenvironment with zoledronate enhances the therapeutic effects of STI571 and paclitaxel against experimental bone metastasis of human prostate cancer. Cancer Res 2005; 65(9): 3707-15.
62. AZURE, does Adjuvant Zoledronic acid red Uce REcurrence in patients with high-risk, localized breast cancer? Trial Protocol 2005; (ISRCTN79831382): 3-57.
63. Coleman RE, Winter MC, Cameron D, et al. The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response - exploratory evidence for direct anti-tumour activity in breast cancer on behalf of the AZURE (BIG01/04) Investigators. BJC 2010; 102(7): 1099-105.
64. Winter MC, Cross SS, Ingram CE, et al. ANZAC: a neoadjuvant biomarker study exploring the anti-tumour activity of the Additi on of Zoledronic Acid to Chemotherapy in breast cancer. Ann Oncol 2009; 20 (Suppl 2): 165P.
65. http://clinicaltrials.gov/ct2/show/NCT00512993.
66. Holen I, Coleman RE. Bisphosphonates as Treatment of Bone Metastases. Curr Pharm Des 2010; 15(11): 1262-71.
67. Rogers MJ. New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des 2003; 9(32): 2643-58.
68. Uludag H. Bisphosphonates as a foundation of drug delivery to bone. Curr Pharm Des 2002; 8(21): 1929-44.